KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Accumulated Depreciation & Amortization (2016 - 2025)

Jazz Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 16 years, most recently at $41.6 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $41.6 million for Q4 2025, up 26.83% from a year ago — trailing twelve months through Dec 2025 was $41.6 million (up 26.83% YoY), and the annual figure for FY2025 was $41.6 million, up 26.83%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $41.6 million at Jazz Pharmaceuticals, down from $171.2 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for JAZZ hit a ceiling of $171.6 million in Q1 2025 and a floor of $26.7 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $97.3 million (2022), compared with a mean of $99.4 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 42.78% in 2021 and later rose 0.33% in 2023.
  • Jazz Pharmaceuticals' Accumulated Depreciation & Amortization stood at $26.7 million in 2021, then rose by 13.48% to $30.3 million in 2022, then grew by 0.33% to $30.4 million in 2023, then grew by 7.89% to $32.8 million in 2024, then rose by 26.83% to $41.6 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $41.6 million (Q4 2025), $171.2 million (Q3 2025), and $166.3 million (Q2 2025) per Business Quant data.